Track topics on Twitter Track topics that are important to you
TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with a commercial product and an advanced clinical stage pipeline of adult stem cell programs.
The company’s lead product, ChondroCelect®, for cartilage repair in the knee, is the only approved cell-based product in Europe, and is currently being launched in different European countries.
TiGenix’s stem cell programs are based on a validated platform of allogeneic expanded adipose-derived stem cells (eASCs) targeting autoimmune and inflammatory diseases. Built on solid pre-clinical and CMC packages, they are being developed in close consultation with the European Medicines Agency. The company has initiated a Phase III clinical trial in complex perianal fistulas in patients with Crohn’s disease, is conducting a Phase IIa trial in rheumatoid arthritis, and successfully concluded a Phase I trial to investigate the potential of intra-lymphatic administration of eASCs for autoimmune disorders.
TiGenix is based out of Leuven (Belgium), and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands).
Haasrode Researchpark 1724
Romeinse straat 12 bus 2
Phone: +32 (0) 16 39 60 60
Fax: +32 (0) 16 39 79 70
Takeda Pharmaceutical (TSE:4502) and TiGenix (Euronext Brussels and Nasdaq:TIG) today announced the results of the first acceptance period of Takeda’s previously announced tender offer in cash f...
Takeda Pharmaceutical has completed its purchase of all outstanding ordinary shares of Belgium-based TiGenix for approximately $608.84m (€520m), representing €1.78...Read More... The post Takeda c...
The European Commission approved TiGenix and Takeda Pharmaceutical's Alofisel, or darvadstrocel, as a treatment for adult pat -More-
Japanese pharma giant Takeda has completed its buyout of TiGenix. Takeda’s main R&D focus is in oncology, gastroenterology and neuroscience therapeutic areas, and vaccines. The company employs ...
In this episode of PharmaTelevision News Review, filmed at BioPartnering Future Europe in Brussels, Fintan Walton talks to Maria Pascual, VP of Regulatory Affairs and Corporate QA at Tigenix
TiGenix says its treatment for complex perianal fistulae in Crohn’s disease is the first allogeneic stem cell to be approved...
TiGenix and Takeda’s Alofisel has won clearance from the European Commission, making it the first allogeneic stem cell therapy to be approved for use in Europe. Alofisel, previously known as ...
Takeda has closed its $630m acquisition of European regenerative medicine company TiGenix following a successful bid process, but is facing...
TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with a commercial product and an advanced clinical stage pipeline of adult stem cell programs. The company’s lead pr...
Ysios Capital is an independent venture capital firm providing private equity financing to early through late-stage human healthcare and biotechnology companies with special focus...
We have published hundreds of TiGenix NV news stories on BioPortfolio along with dozens of TiGenix NV Clinical Trials and PubMed Articles about TiGenix NV for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of TiGenix NV Companies in our database. You can also find out about relevant TiGenix NV Drugs and Medications on this site too.
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...